This program will include a discussion of data that were presented in abstract form These data should be considered preliminary until published in a peerreviewed journal Introduction The Multiple Domains of PsA ID: 775427
Download Presentation The PPT/PDF document " Improving the Diagnosis and Management ..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Improving the Diagnosis and Management of Psoriatic Arthritis
Slide2Slide3This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.
Slide4Introduction
Slide5The Multiple Domains of PsA
Slide6PsA Clinical Presentation
Slide7Common Initial Symptoms in PsA
Slide8Challenges Associated With PsA Diagnosis
Slide9Development of PsA: Red Flags
Slide10Genetic Component in PsA
Slide11Cytokine Pathways Implicated in PsA Pathogenesis
Slide12Prognostic Factors in PsA
Slide13Prognostic Factors in PsA (cont)
Slide14Classification of PsA
Slide15Classification of PsA (cont)
Slide16Early Diagnosis of PsA Is Critical
Slide17Delay in Diagnosis > 6 Months Leads to Poorer Outcomes in PsA
Slide18Key Diagnostic Techniques and Signs for Early Identification and Monitoring of PsA: Expert Perspective
Slide19Key Diagnostic Techniques and Signs for Early Identification and Monitoring of PsA: Expert Perspective (cont)
Slide20Screening Tools in PsA
Slide21Tools to Reduce Referral Delay: PEST
Slide22Advantages of Questionnaires
Slide23The Role of the MDT
Slide24Guidelines for PsA
Slide25GRAPPA Guidelines in PsA: Key Domains
Slide26GRAPPA and EULAR Guidelines: Axial, Enthesitis, and Dactylitis Predominant Disease
Slide27The TICOPA Trial
Slide28TICOPA Trial: Patients Achieving a Response at 48 Weeks
Slide29Does Treat to Target REALLY Matter?
Slide30Treating PsA to Target
Slide31Treating PsA to Target (cont)
Slide32Targets to Consider in PsA
Slide33Treat to Target: Expert Perspective
Slide34Choosing a Target: VLDA/MDA
Slide35Is the Treat-to-Target Approach Practical? Expert Perspective
Slide36Is the Treat-to-Target Approach Practical? Expert Perspective (cont)
Slide37Concluding Remarks
Slide38Abbreviations
Slide39Abbreviations (cont)